FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3146530070> ?p ?o ?g. }

• W3146530070 endingPage "620.e9" @default.
• W3146530070 startingPage "620.e1" @default.
• W3146530070 abstract "Allogeneic hematopoietic cell transplantation (allo-HCT) is a curative treatment option for patients with acute lymphoblastic leukemia (ALL). Both total body irradiation (TBI)-based and chemotherapy only-based myeloablative transplantation conditioning regimens have been applied, but the optimal regimen remains unclear. We performed a systematic review to assess the efficacy of TBI-based versus chemotherapy only-based myeloablative conditioning regimens. We searched PubMed, Embase, and Cochrane databases and meeting abstracts for all studies comparing TBI-based and chemotherapy only-based conditioning regimens in patients who underwent allo-HCT for ALL. Two authors independently reviewed all studies for inclusion and extracted data related to overall survival (OS), progression-free survival (PFS), nonrelapse mortality (NRM), relapse, and acute and chronic graft-versus-host disease (GVHD). Eight studies were included in the final analysis. The overall methodological quality of the included studies was optimal. TBI-based regimens showed evidence of benefit compared with chemotherapy only-based conditioning regimens in terms of relapse (relative risk [RR], 0.82; 95% confidence interval [CI], 0.72 to 0.94; 6 studies, 5091 patients), OS (hazard ratio [HR], 0.76; 95% CI, 0.64 to 0.89; 7 studies, 4727 patients), and PFS (HR, 0.74; 95% CI, 0.63 to 0.85; 7 studies, 4727 patients). The TBI-based regimen did not increase the likelihood of grade II-IV acute GVHD (RR, 1.12; 95% CI, 0.92 to 1.36; 5 studies, 4996 patients) or chronic GVHD (RR, 1.10; 95% CI, 1.00 to 1.21; 5 studies, 4490 patients), or NRM (RR, 0.94; 95% CI, 0.69 to 1.28; 6 studies, 4522 patients). However, TBI-based regimens were associated with an increased risk of grade III-IV acute GVHD (RR, 1.29; 95% CI, 1.01 to 1.63; 3 studies, 3675 patients). A subgroup comparison of patients age ≥16 years showed similar results. This systematic review represents evidence supporting the use of TBI-based conditioning regimen in patients undergoing allo-HCT for ALL who are candidates for myeloablative conditioning, as it offers better OS, PFS, and less relapse with acceptable NRM." @default.
• W3146530070 created "2021-04-13" @default.
• W3146530070 creator A5000462280 @default.
• W3146530070 creator A5004190194 @default.
• W3146530070 creator A5004321777 @default.
• W3146530070 creator A5009719497 @default.
• W3146530070 creator A5015707456 @default.
• W3146530070 creator A5017961539 @default.
• W3146530070 creator A5018552863 @default.
• W3146530070 creator A5021394406 @default.
• W3146530070 creator A5023865265 @default.
• W3146530070 creator A5025137989 @default.
• W3146530070 creator A5035905546 @default.
• W3146530070 creator A5040390930 @default.
• W3146530070 creator A5041095483 @default.
• W3146530070 creator A5047819225 @default.
• W3146530070 creator A5055261814 @default.
• W3146530070 creator A5058144819 @default.
• W3146530070 creator A5062691289 @default.
• W3146530070 creator A5065360941 @default.
• W3146530070 creator A5068862906 @default.
• W3146530070 creator A5076659442 @default.
• W3146530070 creator A5083687455 @default.
• W3146530070 creator A5087799564 @default.
• W3146530070 date "2021-07-01" @default.
• W3146530070 modified "2023-10-06" @default.
• W3146530070 title "Impact of Total Body Irradiation-Based Myeloablative Conditioning Regimens in Patients with Acute Lymphoblastic Leukemia Undergoing Allogeneic Hematopoietic Stem Cell Transplantation: Systematic Review and Meta-Analysis" @default.
• W3146530070 cites W1969143483 @default.
• W3146530070 cites W1980501529 @default.
• W3146530070 cites W1993665924 @default.
• W3146530070 cites W2007234423 @default.
• W3146530070 cites W2031367735 @default.
• W3146530070 cites W2035343180 @default.
• W3146530070 cites W2080130915 @default.
• W3146530070 cites W2088095316 @default.
• W3146530070 cites W2095477156 @default.
• W3146530070 cites W2098923148 @default.
• W3146530070 cites W2104675861 @default.
• W3146530070 cites W2128491464 @default.
• W3146530070 cites W2148207894 @default.
• W3146530070 cites W2195410532 @default.
• W3146530070 cites W2318054878 @default.
• W3146530070 cites W2529889366 @default.
• W3146530070 cites W2576440140 @default.
• W3146530070 cites W2737044511 @default.
• W3146530070 cites W2774624088 @default.
• W3146530070 cites W2807317397 @default.
• W3146530070 cites W2936876518 @default.
• W3146530070 cites W2989604187 @default.
• W3146530070 cites W3042733495 @default.
• W3146530070 cites W66769540 @default.
• W3146530070 doi "https://doi.org/10.1016/j.jtct.2021.03.026" @default.
• W3146530070 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33798768" @default.
• W3146530070 hasPublicationYear "2021" @default.
• W3146530070 type Work @default.
• W3146530070 sameAs 3146530070 @default.
• W3146530070 citedByCount "18" @default.
• W3146530070 countsByYear W31465300702022 @default.
• W3146530070 countsByYear W31465300702023 @default.
• W3146530070 crossrefType "journal-article" @default.
• W3146530070 hasAuthorship W3146530070A5000462280 @default.
• W3146530070 hasAuthorship W3146530070A5004190194 @default.
• W3146530070 hasAuthorship W3146530070A5004321777 @default.
• W3146530070 hasAuthorship W3146530070A5009719497 @default.
• W3146530070 hasAuthorship W3146530070A5015707456 @default.
• W3146530070 hasAuthorship W3146530070A5017961539 @default.
• W3146530070 hasAuthorship W3146530070A5018552863 @default.
• W3146530070 hasAuthorship W3146530070A5021394406 @default.
• W3146530070 hasAuthorship W3146530070A5023865265 @default.
• W3146530070 hasAuthorship W3146530070A5025137989 @default.
• W3146530070 hasAuthorship W3146530070A5035905546 @default.
• W3146530070 hasAuthorship W3146530070A5040390930 @default.
• W3146530070 hasAuthorship W3146530070A5041095483 @default.
• W3146530070 hasAuthorship W3146530070A5047819225 @default.
• W3146530070 hasAuthorship W3146530070A5055261814 @default.
• W3146530070 hasAuthorship W3146530070A5058144819 @default.
• W3146530070 hasAuthorship W3146530070A5062691289 @default.
• W3146530070 hasAuthorship W3146530070A5065360941 @default.
• W3146530070 hasAuthorship W3146530070A5068862906 @default.
• W3146530070 hasAuthorship W3146530070A5076659442 @default.
• W3146530070 hasAuthorship W3146530070A5083687455 @default.
• W3146530070 hasAuthorship W3146530070A5087799564 @default.
• W3146530070 hasConcept C126322002 @default.
• W3146530070 hasConcept C141071460 @default.
• W3146530070 hasConcept C143998085 @default.
• W3146530070 hasConcept C207103383 @default.
• W3146530070 hasConcept C2776694085 @default.
• W3146530070 hasConcept C2776755627 @default.
• W3146530070 hasConcept C2777408962 @default.
• W3146530070 hasConcept C2778880498 @default.
• W3146530070 hasConcept C2781413609 @default.
• W3146530070 hasConcept C2911091166 @default.
• W3146530070 hasConcept C44249647 @default.
• W3146530070 hasConcept C71924100 @default.
• W3146530070 hasConceptScore W3146530070C126322002 @default.
• W3146530070 hasConceptScore W3146530070C141071460 @default.
• W3146530070 hasConceptScore W3146530070C143998085 @default.
• W3146530070 hasConceptScore W3146530070C207103383 @default.

• next